avian
influenza
viru
caus
outbreak
domest
wild
bird
around
world
sporad
human
infect
report
dna
vaccin
encod
hemagglutinin
ha
protein
strain
initi
test
two
random
phase
clinic
studi
vaccin
research
center
studi
vrc
doubleblind
studi
subject
random
placebo
mg
vaccin
mg
vaccin
treatment
group
n
intramuscular
im
biojector
inject
vrc
openlabel
studi
evalu
rout
subject
random
intraderm
id
inject
mg
needlesyring
biojector
mg
deliv
two
biojector
inject
deltoid
mg
deltoid
n
inject
administ
week
studi
antibodi
respons
assess
hemagglutin
inhibit
hai
assay
enzymelink
immunosorb
assay
elisa
neutral
assay
cell
respons
assess
enzymelink
immunospot
intracellular
cytokin
stain
assay
vaccinerel
seriou
advers
event
vaccin
well
toler
group
mg
id
vaccin
compar
im
vaccin
induc
greater
frequenc
magnitud
respons
elisa
signific
differ
frequenc
magnitud
respons
id
im
rout
hai
neutral
assay
cell
respons
common
subject
receiv
dose
im
studi
demonstr
dna
vaccin
encod
safe
immunogen
serv
defin
proper
dose
rout
studi
id
inject
rout
offer
signific
advantag
im
rout
differ
detect
deliveri
one
site
versu
split
dose
two
site
id
vaccin
administr
dose
im
investig
primeboost
regimen
h
ighli
pathogen
avian
influenza
virus
caus
widespread
diseas
domest
bird
popul
capac
caus
diseas
human
pose
threat
public
health
world
health
organ
report
august
confirm
human
case
death
sever
ill
high
mortal
rate
possibl
humantohuman
spread
serv
incent
develop
human
vaccin
avian
influenza
virus
protect
influenza
antibodymedi
respons
influenza
vaccin
typic
measur
hemagglutin
inhibit
hai
assay
hai
titer
associ
least
reduct
influenza
ill
enzymelink
immunosorb
assay
elisa
detect
bind
antibodi
neutral
antibodi
assay
detect
antibodi
capac
inhibit
viral
entri
cell
vitro
assay
investig
influenza
vaccin
studi
clinic
trial
gener
immunogen
assess
primarili
hai
less
seen
tradit
season
influenza
vaccin
antigen
attempt
improv
immun
respons
vaccin
includ
increas
dose
ad
addit
antigen
na
np
homolog
boost
combin
genebas
vaccin
electropor
addit
adjuv
result
modest
increas
hai
titer
preclin
clinic
studi
vaccin
research
center
vrc
strategi
improv
influenza
vaccin
immunogen
includ
util
genebas
vector
primeboost
regimen
earli
studi
describ
assess
safeti
immunogen
dna
product
vaccin
administ
threedos
regimen
without
heterolog
vaccin
boost
similar
regimen
use
initi
evalu
genebas
vaccin
sever
acut
respiratori
syndrom
west
nile
viru
ebola
viru
addit
intramuscular
im
administr
evalu
potenti
impact
intraderm
id
administr
immun
respons
overal
vaccin
well
toler
rout
dose
vaccin
immunogen
previou
vaccin
clinic
trial
overal
respons
modest
dna
given
without
inactiv
vaccin
boost
evalu
vaccin
shown
promis
prime
inactiv
vaccin
boost
studi
repres
first
clinic
studi
product
human
examin
safeti
immunogen
investig
dna
vaccin
encod
ha
influenza
recommend
world
health
organ
clade
candid
vaccin
viru
http
wwwwhointcsrdiseaseavian
dose
administ
intramuscularli
im
intraderm
id
vrc
vrc
studi
respect
healthi
adult
age
year
studi
review
approv
niaid
institut
review
board
us
depart
health
human
servic
human
experiment
guidelin
conduct
clinic
research
follow
vrc
trial
dose
mg
evalu
along
placebo
volunt
concurr
random
three
studi
group
volunt
per
group
group
studi
inject
administ
im
use
biojector
needlefre
inject
system
day
vrc
studi
volunt
concurr
random
four
studi
group
subject
per
group
receiv
vaccin
day
group
receiv
mg
ml
dna
vaccin
per
inject
administ
id
biojector
group
receiv
mg
ml
dna
vaccin
per
inject
administ
id
use
needl
syring
group
receiv
mg
dna
vaccin
administ
id
biojector
two
inject
mg
ml
deltoid
muscl
sidebysid
inject
group
receiv
mg
dna
vaccin
administ
id
biojector
two
inject
mg
ml
one
inject
deltoid
studi
safeti
monitor
includ
laboratori
clinic
evalu
schedul
studi
visit
local
system
reactogen
solicit
day
vaccin
advers
event
code
use
medic
dictionari
regulatori
activ
grade
sever
scale
rang
subject
monitor
safeti
immunogen
period
week
vaccin
dna
vaccin
manufactur
vrcniaidvaccin
pilot
plant
oper
saic
frederick
md
consist
singl
closedcircular
plasmid
dna
macromolecul
express
influenza
ha
sequenc
deriv
human
isol
influenza
viru
sequenc
databas
lo
alamo
nation
laboratori
databas
plasmid
contain
cmvr
promot
previous
describ
plasmid
dna
prepar
good
manufactur
practic
mgml
phosphatebuff
salin
pb
placebo
pb
statist
method
antibodi
cell
respons
posit
respons
rate
exact
confid
interv
report
respons
magnitud
posit
respond
report
geometr
mean
confid
interv
antibodi
respons
ha
assess
elisa
hai
assay
neutral
assay
compar
studi
group
use
fisher
exact
test
respons
rate
wilcoxon
test
respons
magnitud
sampl
process
cell
prepar
peripher
blood
mononuclear
cell
pbmc
prepar
standard
ficollhypaqu
densiti
gradient
centrifug
pharmacia
uppsala
sweden
pbmc
frozen
heatinactiv
fetal
calf
serum
contain
dimethyl
sulfoxid
forma
cryom
cell
freezer
marietta
oh
store
assay
perform
thaw
specimen
averag
viabil
measur
antibodi
respons
elisa
endpoint
titer
antibodi
direct
antigen
immun
technolog
corp
new
york
ny
determin
use
dynex
technolog
plate
coat
prepar
purifi
recombin
protein
accord
method
adapt
previous
describ
endpoint
titer
calcul
dilut
serum
concentr
gave
optic
densiti
background
measur
neutral
antibodi
neutral
antibodi
evalu
capac
sera
prevent
infect
cell
replicationincompet
hapseudotyp
viru
pseudotyp
viru
express
antigen
luciferas
report
gene
neutral
activ
quantifi
rel
decreas
luciferas
activ
compar
infect
cell
absenc
sera
base
previous
describ
method
inhibit
serum
titer
id
calcul
rel
signal
absenc
sera
use
fiveparamet
curv
fit
measur
antibodi
respons
hai
assay
hai
assay
perform
vbottom
plate
use
four
hemagglutin
unit
viru
hors
erythrocyt
previous
describ
viru
strain
use
hai
assay
lowpathogen
reassort
obtain
ruben
doni
cdc
influenza
branch
atlanta
ga
clade
cell
respons
assess
intracellular
cytokin
stain
ic
gamma
interferon
enzymelink
immunospot
assay
elispot
previous
describ
ic
elispot
analys
stimul
via
vaccin
insertmatch
peptid
overlap
posit
respons
ic
occur
fisher
exact
test
tabl
consist
posit
neg
cell
peptid
neg
control
onesid
p
valu
percent
posit
cell
peptid
minu
percent
posit
cell
neg
control
backgroundsubtract
percentag
exce
posit
elispot
respons
occur
backgroundsubtract
number
spot
per
cell
exce
nonbackgroundcorrect
mean
least
greater
mean
neg
stimul
sampl
studi
popul
demograph
vaccin
safeti
baselin
demograph
shown
tabl
vrc
subject
women
white
africanamerican
mean
age
time
enrol
year
vrc
women
white
africanamerican
mean
age
time
enrol
year
studi
subject
report
highest
educ
level
either
colleg
advanc
degre
vrc
subject
group
receiv
three
inject
dose
one
subject
lost
followup
receiv
studi
inject
move
area
two
subject
group
discontinu
vaccin
two
immun
need
system
corticosteroid
unrel
vaccin
two
subject
lost
followup
group
placebo
group
one
particip
withdrew
one
studi
inject
one
subject
placebo
group
complet
visit
except
week
due
move
area
subject
complet
studi
visit
week
safeti
monitor
vrc
nine
subject
withdrawn
vaccin
schedul
two
group
three
group
one
group
three
group
reason
relat
intercurr
ill
need
contraind
medic
five
subject
noncompli
protocol
schedul
lost
followup
three
subject
vrc
subject
complet
vaccin
complet
protocol
week
safeti
monitor
fig
studi
vaccin
well
toler
seriou
advers
event
relat
vaccin
either
studi
advers
event
assess
relat
id
vaccin
vrc
includ
mild
superfici
skin
lesion
heal
without
sequela
subject
mild
itchi
pruriti
report
subject
solicit
reactogen
categor
group
present
tabl
across
three
group
vrc
worst
sever
local
reactogen
report
none
mild
moder
subject
moder
symptom
pain
inject
site
report
placebo
recipi
worst
sever
system
reactogen
report
none
mild
moder
subject
moder
symptom
report
placebo
group
one
placebo
subject
return
diari
card
therefor
miss
reactogen
data
across
four
group
vrc
worst
sever
local
reactogen
report
none
mild
subject
overal
across
studi
worst
sever
system
reactogen
report
none
mild
moder
subject
addit
appar
trend
toward
increas
reactogen
sequenti
dose
even
highest
dose
either
studi
see
tabl
supplement
materi
sever
reactogen
either
studi
influenza
virusspecif
antibodi
respons
primari
time
point
immun
assess
studi
week
third
inject
week
studi
subject
neg
antibodi
hai
assay
elisa
neutral
antibodi
nt
assay
baselin
week
frequenc
posit
hai
neutral
respons
slightli
higher
subject
receiv
mg
im
group
fig
c
compar
rout
administr
mg
id
vrc
deliv
divid
dose
deltoid
divid
deltoid
induc
higher
frequenc
respons
higher
elisa
titer
fig
mg
im
vrc
rout
effect
dose
seen
hai
neutral
dose
induc
neglig
hai
neutral
respons
none
respons
reach
posit
criteria
fig
c
signific
differ
seen
assay
compar
mg
deliv
divid
dose
inject
given
deltoid
compar
divid
dose
singl
inject
given
deltoid
antigen
specif
tcell
respons
assess
elispot
assay
ic
week
fig
rate
elispotposit
respons
greatest
group
receiv
mg
im
mg
im
mg
use
bioject
id
two
arm
rate
ic
respons
gener
low
highest
frequenc
respons
seen
im
group
tcell
respons
detect
ic
frequent
cell
respons
rate
ic
respons
highest
subject
receiv
mg
im
respect
subject
receiv
mg
id
biojector
one
arm
two
arm
respect
pattern
differ
suggest
dose
effect
overal
cell
respons
con
sistent
among
group
vrc
studi
im
rout
vrc
studi
id
rout
safe
highli
efficaci
platform
vaccin
remain
elus
despit
attempt
optim
antigen
vehicl
deliveri
regimen
adjuv
formul
antigen
gener
less
immunogen
season
influenza
antigen
pose
difficult
scientif
challeng
vaccin
research
studi
demonstr
dna
vaccin
encod
safe
immunogen
given
threedos
regimen
without
heterolog
boost
induc
modest
immunogen
surprisingli
dose
effect
observ
mg
im
induc
higher
antibodi
cell
respons
compar
mg
im
mg
id
vrc
studi
one
question
focus
distribut
dose
relat
question
split
dose
differ
limb
two
group
receiv
mg
id
divid
two
dose
one
group
inject
administ
deltoid
group
one
inject
administ
deltoid
present
studi
signific
differ
relat
safeti
antibodi
cell
respons
two
group
studi
import
establish
safeti
immunogen
vaccin
prior
evalu
primeboost
regimen
dose
mg
im
impress
immun
respons
seen
follow
vaccin
boost
dna
vaccin
administ
without
boost
shown
elicit
robust
immun
respons
impress
immunogen
relat
dna
vaccin
continu
seen
dna
vaccin
use
prime
boost
heterolog
vaccin
vector
protein
includ
dna
vaccin
base
impress
safeti
record
improv
manufactur
immunogen
dna
vaccin
well
recent
find
describ
signific
impact
dna
prime
monoval
inactiv
vaccin
boost
evalu
dna
vaccin
primeboost
regimen
toward
improv
influenza
vaccin
warrant
